Furthermore, although the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors has been demonstrated for HF across all LVEF categories,11,12 these cohorts include patients with various underlying heart diseases and still have residual heterogeneity. This evidence concerns the gene SLC5A2 and heart disorder.